|
JP2013129661A
|
|
Therapeutic agent for amyotrophic lateral sclerosis
|
|
JP2011173916A
|
|
Therapeutic agent of amyotrophic lateral sclerosis
|
|
JP2007277268A
|
|
Agent for treatment of fulminant hepatitis
|
|
JP2006131649A
|
|
Pulmonary fibrosis preventive agent
|
|
JP2005237373A
|
|
Sugar chain-deficient type hgf alpha chain partial protein
|
|
JP2004269538A
|
|
Mature recombinant hepatocyte growth factor
|
|
JP2001190293A
|
|
Recombinant hepatocyte growth factor
|
|
JP2002087983A
|
|
Treating agent for amyotrophic lateral sclerosis
|
|
JPH114696A
|
|
Recombinant hepatocyte growth factor
|
|
JPH10191991A
|
|
Recombinant human hepatocyte growth factor and its production
|
|
JPH1070990A
|
|
Recombinant hepatic parenchymatous cell multiplier
|
|
JPH10167982A
|
|
Therapeutic agent for fulminant hepatitic disease
|
|
JPH09110716A
|
|
Anticancer agent
|
|
JPH07300426A
|
|
Collagen decomposition promoter
|
|
JPH07258111A
|
|
Agent for reducing side effect of immunosuppressant
|
|
JPH0789869A
|
|
Therapeutic agent for cerebral nerve disorder
|
|
JPH07138183A
|
|
Therapeutic agent for disease in stomach and duodenum
|
|
JPH06312941A
|
|
Hgf production promoter
|
|
JPH06172207A
|
|
Pulmonary injury-treating agent
|
|
JPH0640938A
|
|
Hgf-containing pharmaceutical preparation
|
